

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A prophylactic or therapeutic agent for viral myocarditis, comprising as an active ingredient, 2-[4-(diphenylmethyl)-1-piperazinyl]-acetic acid or amide derivative, an individual optical isomer or a pharmaceutically acceptable salt thereof.
2. (Original) A prophylactic or therapeutic agent for viral myocarditis according to claim 1, wherein the viral myocarditis is caused by RNA virus or hepatitis virus.
3. (Original) A prophylactic or therapeutic agent for viral myocarditis according to claim 2, wherein the RNA virus is orthomyxovirus or picornavirus.
4. (Original) A prophylactic or therapeutic agent for viral myocarditis-related viral disease comprising as an active ingredient, 2-[4-(diphenylmethyl)-1-piperazinyl]-acetic acid or amide derivative, an individual optical isomer or a pharmaceutically acceptable salt thereof.
5. (Original) A prophylactic or therapeutic agent for viral disease according to claim 4, wherein the viral myocarditis-related viral disease is caused by RNA virus or hepatitis virus.
6. (Original) A prophylactic or therapeutic agent for viral disease according to claim 5, wherein the RNA virus is orthomyxovirus or picornavirus.
7. (Currently Amended) A prophylactic or therapeutic agent for viral disease according to claim 4, wherein the viral disease is selected from the group consisting of viral hepatitis (~~hepatitis A, hepatitis B, hepatitis C, hepatitis E, hepatitis G~~), adenovirus infection, influenza, herpes infection, viral encephalitis, cytomegalovirus infection, viral enteritis or viral pericarditis.
8. (Original) An agent for healing or preventing viral cytotoxic injury, comprising as an active ingredient, 2-[4-(diphenylmethyl)-1-piperazinyl]-acetic acid or amide derivative, an individual optical isomer or a pharmaceutically acceptable salt thereof.
- 9 – 10 (Canceled)

11. (New) A method of preventing or treating viral myocarditis-related viral disease in a patient comprising administering to the patient a therapeutically effective amount of a compound selected from 2-[4-(diphenylethyl)-1-piperazinyl]-acetic acid, an amide derivative thereof, an individual optical isomer thereof, and a pharmaceutically acceptable salt one of the foregoing.
12. (New) The method according to claim 11 wherein the compound is selected from the group consisting [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-acetic acid, its dihydrochloride salt or its levorotatory enantiomer; 2-[2-[4-bis(4-fluorophenyl)methyl]-1-piperazinyl]ethoxy]acetic acid or its dihydrochloride salt 5-[4-[(aminocarbonyl)(hydroxy)amino]but-1-ynyl]-2-[2-[4-[(R)-[4-chlorophenyl](phenyl)methyl]piperazin-1-yl]ethoxy]benzamide or a pharmaceutically acceptable salt thereof; and N-[4-[4-[2-[4-[(R)-[4-chlorophenyl](phenyl)methyl]-1-piperazinyl]ethoxy]phenyl]-3-butynyl]-N-hydroxyurea or a pharmaceutically acceptable salt thereof.
13. (New) A composition comprising (a) a compound selected from 2-[4-(diphenylethyl)-1-piperazinyl]-acetic acid, amide derivative thereof, an individual optical isomer thereof, and a pharmaceutically acceptable salt thereof and (b) a pharmaceutically acceptable carrier, excipient, or diluent.
14. (New) The composition according to claim 13 wherein the compound is selected from the group consisting [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-acetic acid, its dihydrochloride salt or its levorotatory enantiomer; 2-[2-[4-bis(4-fluorophenyl)methyl]-1-piperazinyl]ethoxy]acetic acid or its dihydrochloride salt 5-[4-[(aminocarbonyl)(hydroxy)amino]but-1-ynyl]-2-[2-[4-[(R)-[4-chlorophenyl](phenyl)methyl]piperazin-1-yl]ethoxy]benzamide or a pharmaceutically acceptable salt thereof; and N-[4-[4-[2-[4-[(R)-[4-chlorophenyl](phenyl)methyl]-1-piperazinyl]ethoxy]phenyl]-3-butynyl]-N-hydroxyurea or a pharmaceutically acceptable salt thereof.